# Sagimet Biosciences Inc.: financial statements, quarterly

SGMT · Nasdaq · CIK 1400118 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sgmt.md) · [Financials](/companies/sgmt/financials.md) · [Filings](/companies/sgmt/filings.md) · [Insiders](/companies/sgmt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sgmt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.0](/filings/0001558370-24-015623.md) | [0.0 d](/filings/0001558370-25-002747.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [5.0](/filings/0001558370-24-015623.md) | [5.7 d](/filings/0001558370-25-002747.md) | [5.3](/filings/0001558370-25-006836.md) | [6.3](/filings/0001558370-25-011301.md) | [12.7](/filings/0001104659-25-110846.md) | [14.2 d](/filings/0001104659-26-026140.md) | [15.3](/filings/0001104659-26-059006.md) | [7.2](/filings/0001193125-26-343441.md) | [9.7](/filings/0001104659-25-110846.md) | [6.7 d](/filings/0001104659-26-026140.md) | [7.0](/filings/0001104659-26-059006.md) | [11.5](/filings/0001193125-26-343441.md) |
| Operating income | $m | [(7.5)](/filings/0001558370-24-015623.md) | [(9.5) d](/filings/0001558370-25-002747.md) | [(8.8)](/filings/0001558370-25-006836.md) | [(10.6)](/filings/0001558370-25-011301.md) | [(16.9)](/filings/0001104659-25-110846.md) | [(18.2) d](/filings/0001104659-26-026140.md) | [(19.9)](/filings/0001104659-26-059006.md) | [(11.9)](/filings/0001193125-26-343441.md) | [(14.3)](/filings/0001104659-25-110846.md) | [(10.8) d](/filings/0001104659-26-026140.md) | [(11.7)](/filings/0001104659-26-059006.md) | [(15.8)](/filings/0001193125-26-343441.md) |
| Net income | $m | [(6.4)](/filings/0001558370-24-015623.md) | [(8.2) d](/filings/0001558370-25-002747.md) | [(6.6)](/filings/0001104659-25-110846.md) | [(8.1)](/filings/0001104659-25-110846.md) | [(14.6)](/filings/0001104659-25-110846.md) | [(16.2) d](/filings/0001104659-26-026140.md) | [(18.2)](/filings/0001193125-26-343441.md) | [(10.4)](/filings/0001193125-26-343441.md) | [(12.9)](/filings/0001104659-25-110846.md) | [(9.6) d](/filings/0001104659-26-026140.md) | [(10.7)](/filings/0001193125-26-343441.md) | [(14.0)](/filings/0001193125-26-343441.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0001558370-24-015623.md) | not reported | [(0.23)](/filings/0001558370-25-006836.md) | [(0.25)](/filings/0001558370-25-011301.md) | [(0.45)](/filings/0001104659-25-110846.md) | not reported | [(0.56)](/filings/0001104659-26-059006.md) | [(0.32)](/filings/0001193125-26-343441.md) | [(0.40)](/filings/0001104659-25-110846.md) | not reported | [(0.33)](/filings/0001104659-26-059006.md) | [(0.26)](/filings/0001193125-26-343441.md) |
| Basic EPS | $ per share | [(0.35)](/filings/0001558370-24-015623.md) | not reported | [(0.23)](/filings/0001558370-25-006836.md) | [(0.25)](/filings/0001558370-25-011301.md) | [(0.45)](/filings/0001104659-25-110846.md) | not reported | [(0.56)](/filings/0001104659-26-059006.md) | [(0.32)](/filings/0001193125-26-343441.md) | [(0.40)](/filings/0001104659-25-110846.md) | not reported | [(0.33)](/filings/0001104659-26-059006.md) | [(0.26)](/filings/0001193125-26-343441.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [102](/filings/0001558370-23-018700.md) | [75.1](/filings/0001558370-25-002747.md) | [177](/filings/0001558370-24-008205.md) | [96.0](/filings/0001558370-24-012136.md) | [77.0](/filings/0001558370-24-015623.md) | [75.8](/filings/0001104659-26-026140.md) | [64.7](/filings/0001558370-25-006836.md) | [42.3](/filings/0001558370-25-011301.md) | [32.5](/filings/0001104659-25-110846.md) | [35.0](/filings/0001193125-26-343441.md) | [36.6](/filings/0001104659-26-059006.md) | [166](/filings/0001193125-26-343441.md) |
| Current assets | $m | [103](/filings/0001558370-23-018700.md) | [96.6](/filings/0001558370-25-002747.md) | [194](/filings/0001558370-24-008205.md) | [167](/filings/0001558370-24-012136.md) | [157](/filings/0001558370-24-015623.md) | [153](/filings/0001104659-26-026140.md) | [146](/filings/0001558370-25-006836.md) | [127](/filings/0001558370-25-011301.md) | [119](/filings/0001104659-25-110846.md) | [116](/filings/0001193125-26-343441.md) | [108](/filings/0001104659-26-059006.md) | [244](/filings/0001193125-26-343441.md) |
| Total assets | $m | [103](/filings/0001558370-23-018700.md) | [96.7](/filings/0001558370-25-002747.md) | [195](/filings/0001558370-24-008205.md) | [189](/filings/0001558370-24-012136.md) | [175](/filings/0001558370-24-015623.md) | [160](/filings/0001104659-26-026140.md) | [146](/filings/0001558370-25-006836.md) | [137](/filings/0001558370-25-011301.md) | [128](/filings/0001104659-25-110846.md) | [116](/filings/0001193125-26-343441.md) | [108](/filings/0001104659-26-059006.md) | [263](/filings/0001193125-26-343441.md) |
| Current liabilities | $m | [5.0](/filings/0001558370-23-018700.md) | [5.7](/filings/0001558370-25-002747.md) | not reported | not reported | not reported | [4.5](/filings/0001104659-26-026140.md) | not reported | [7.2](/filings/0001558370-25-011301.md) | [9.1](/filings/0001104659-25-110846.md) | [5.1](/filings/0001193125-26-343441.md) | [5.3](/filings/0001104659-26-059006.md) | [5.4](/filings/0001193125-26-343441.md) |
| Total liabilities | $m | [5.1](/filings/0001558370-23-018700.md) | [5.7](/filings/0001558370-24-015623.md) | [4.5](/filings/0001558370-24-008205.md) | [5.7](/filings/0001558370-24-012136.md) | [4.1](/filings/0001558370-24-015623.md) | [4.5](/filings/0001558370-25-006836.md) | [7.2](/filings/0001558370-25-006836.md) | not reported | not reported | [5.1](/filings/0001193125-26-343441.md) | not reported | [7.3](/filings/0001193125-26-343441.md) |
| Shareholders' equity | $m | [97.9](/filings/0001558370-24-015623.md) | [91.1](/filings/0001104659-26-026140.md) | [190](/filings/0001104659-25-110846.md) | [183](/filings/0001104659-25-110846.md) | [171](/filings/0001104659-25-110846.md) | [156](/filings/0001193125-26-343441.md) | [139](/filings/0001193125-26-343441.md) | [130](/filings/0001193125-26-343441.md) | [119](/filings/0001104659-25-110846.md) | [111](/filings/0001193125-26-343441.md) | [102](/filings/0001193125-26-343441.md) | [256](/filings/0001193125-26-343441.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.9) d](/filings/0001558370-24-015623.md) | [(7.1) d](/filings/0001558370-25-002747.md) | [(6.2)](/filings/0001558370-25-006836.md) | [(5.6) d](/filings/0001558370-25-011301.md) | [(19.6) d](/filings/0001104659-25-110846.md) | [(11.0) d](/filings/0001104659-26-026140.md) | [(14.5)](/filings/0001104659-26-059006.md) | [(9.1) d](/filings/0001193125-26-343441.md) | [(10.2) d](/filings/0001104659-25-110846.md) | [(11.8) d](/filings/0001104659-26-026140.md) | [(8.6)](/filings/0001104659-26-059006.md) | [(11.1) d](/filings/0001193125-26-343441.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.2](/filings/0001558370-23-018700.md) | [0.2](/filings/0001558370-24-008205.md) | [0.2](/filings/0001558370-24-012136.md) | [18.2](/filings/0001558370-24-015623.md) | [29.0](/filings/0001558370-25-006836.md) | [31.9](/filings/0001558370-25-011301.md) | [32.1](/filings/0001104659-25-110846.md) | [32.2](/filings/0001104659-26-059006.md) | [32.2](/filings/0001193125-26-343441.md) | [32.5](/filings/0001104659-25-110846.md) | [32.6](/filings/0001104659-26-059006.md) | [53.1](/filings/0001193125-26-343441.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,674,855 at 2024-11-08, from the cover of the [10-Q filed 2024-11-14](/filings/0001558370-24-015623.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.